BioSapien, the United Arab Emirates health technology firm, has successfully extended its pre-Series A funding round to $7 million.
This achievement by the startup is anchoring UAE’s position as a global medtech hub, according to a press release.
The platform will use the investment to tackle escalating cancer rates by leveraging advanced 3D printing technology.
MediChip™ offers an advanced approach to deliver localised treatment, reducing systemic side effects, and improving patient outcomes.
The funding will accelerate clinical trials in the UAE for MediChip™, BioSapien’s patented 3D-printed, slow-release drug delivery platform.
Go deeper on GCC & Africa tech — $9.99/month.
Deep dives and investor insights the free digest doesn't cover.
Additionally, the capital will be allocated to product development and scaling manufacturing capabilities.
The extension follows December’s $5.50 million pre-Series A funding round, which was led by MENA’s leading VC firm Global Ventures, with additional participation from Dara Holdings.
Khatija Ali, CEO and Founder of BioSapien, said: “Together, we are working towards a future where localized cancer treatment becomes the global standard.”
Michael Lints, Partner at Golden Gate Ventures MENA, commented: “Investing in BioSapien aligns with our commitment to supporting transformative technologies that address significant global challenges.”
“This investment not only supports a groundbreaking technology but also reinforces the Gulf region’s role as a global leader in healthcare innovation,” Lints added.
Engagement
